Skip to main content
SpringerLink
Log in

Congenital CMV disease substantial burden in the US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.

Reference

  • Meyers J, et al. The Economic Burden of Congenital Cytomegalovirus Disease in the First Year of Life: A Retrospective Analysis of Health Insurance Claims Data in the United States. Clinical Therapeutics : 16 May 2019. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.04.022

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Congenital CMV disease substantial burden in the US. PharmacoEcon Outcomes News 829, 5 (2019). https://doi.org/10.1007/s40274-019-5919-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5919-1

Search

Navigation